Day: August 15, 2022

– On Track for Updates on pheEDIT and juMPStart Programs by End of 2022 – – Prioritized Pipeline, Shifting Resources to HMI-103 PKU Gene Editing Trial in Adults While Pausing Enrollment in HMI-102 PKU Gene Therapy Trial Also in Adults – – Received Clearance from Health Canada for juMPStart Trial of Investigational HMI-203 Gene Therapy for Hunter Syndrome and U.S. FDA Orphan Drug Designation – – Announced Optimized MLD Gene Therapy Development Candidate with Plans to Seek a Partner for Program – – Finished Second Quarter 2022 with Strong Cash Position and Extended Runway with Pipeline Prioritization – BEDFORD, Mass., Aug. 15, 2022 (GLOBE NEWSWIRE) — Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today financial results for the second quarter...

MINNEAPOLIS, Aug. 15, 2022 (GLOBE NEWSWIRE) — Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today provides a business update and reports financial results for the quarter ended June 30, 2022. Management is hosting an earnings conference call today at 4:30 p.m. ET. The second quarter was marked by meaningful progress. Q2 and Recent Highlights:First Patient Enrolled in its Aspire Trial. Received approval from the Australian Human Research Ethics Committee (HREC) to expand the company’s global clinical trial to Australia. Closed on the acquisition of Cancer Prevention Pharmaceuticals, Inc. (CPP). Hosted a virtual R&D Day on the company’s investigational drug, ivospemin (SBP-101), as a polyamine metabolism...

Revenue of $51.1 million, up 38%Gross profit of $15.3 million, up 91%Gross margin of 30%, up 840 bps LOS ANGELES, Aug. 15, 2022 (GLOBE NEWSWIRE) — Enthusiast Gaming Holdings Inc. (“Enthusiast Gaming” or the “Company”) (NASDAQ:EGLX; TSX:EGLX), an integrated gaming entertainment company, today announced financial results for the three and six months ended June 30, 2022. “During the first half of 2022, we delivered our strongest half-year results to date, led by accelerated revenue growth and substantial gross margin expansion. Q2 2022 was strong, with gross profit up 91% versus Q2 2021, driven by more subscription revenue and higher direct sales with repeat and new customers,” commented Adrian Montgomery, CEO of Enthusiast Gaming. “These results were made possible by the commitment and dedication of our over 250 global staff that...

FOR IMMEDIATE RELEASE           NEWSAugust 15, 2022 NYSE: NGS   Natural Gas Services Group, Inc. Reports Second Quarter 2022 Financial and Operating Results Second Quarter 2022 HighlightsRental revenue of $18.1 million, an increase of 16% when compared to the second quarter of 2021 and 6% when compared to the first quarter of 2022. Net loss of $70,000 ($0.01 loss per basic and diluted share) an increase of $1,848,000 when compared to the second quarter of 2021 while a decrease in income of $407,000 when compared to the first quarter of 2022. Adjusted EBITDA of $6.7 million an increase of 49% when compared to the second quarter of 2021 and a 2% decrease when compared to the first quarter of 2022. Please see Non-GAAP Financial Measures – Adjusted EBITDA, below.Midland, Texas, Aug. 15, 2022 (GLOBE NEWSWIRE) —...

Navitas Semiconductor Navitas SemiconductorRevenues Increased 58% with important market and regional diversification, while guidance reflects short-term China smartphone softness 20+ significant new wins in mobile chargers, plus accelerating progress in customer development in the solar, EV, data center and industrial markets GeneSiC acquisition positions Navitas as the only pure-play, next-generation power semiconductor company with broad diversification, synergistic customers and 2-3 year acceleration into strategic EV, solar and energy storage marketsEL SEGUNDO, Calif., Aug. 15, 2022 (GLOBE NEWSWIRE) — Navitas Semiconductor Corporation (Nasdaq: NVTS), the industry leader in next-generation power semiconductors, today announced unaudited financial results for the second quarter ended June 30, 2022. Net revenues for the...

DALLAS, Aug. 15, 2022 (GLOBE NEWSWIRE) — Hallmark Financial Services, Inc. (“Hallmark”) (NASDAQ: HALL) today announced financial results for the second quarter and six months ended June 30, 2022.  Second Quarter   Year-to-Date    2022 2021   2022 2021  $ in millions:            Net (Loss) Income $ (69.4 ) $ (0.8 )   $ (72.6 ) $ 8.1  Operating (Loss) Income (1) $ (42.4 ) $ (3.9 )   $ (45.6 ) $ 0.5               $ per diluted share:            Net (Loss) Income $ (3.82 ) $ (0.05 )   $ (4.00 ) $ 0.45  Operating (Loss) Income (1) $ (2.33 ) $ (0.22 )   $ (2.51 ) $ 0.03  (1)   See “Non-GAAP Financial Measures” below Highlights:Net loss of $69.4 million, or $3.82 per share, in the second quarter of 2022 as compared to a net loss of $0.8 million, or $0.05 per share, for the same period of 2021. Year-to-date...

FORT WORTH, Texas, Aug. 15, 2022 (GLOBE NEWSWIRE) — Tandy Leather Factory, Inc. (Pink: TLFA) today announced the Company’s financial results for the second quarter ended June 30, 2022. Second Quarter Highlights:Net sales of $18.4 million Gross profit of $10.5 million and a gross margin of 57.0% Operating loss of $0.7 million Net loss of $0.6 million, or $0.07 per diluted share Adjusted EBITDA* of ($0.1 million) Ended the quarter with $5.6 million in cash and cash equivalentsJanet Carr, Chief Executive Officer of the Company, said, “Our second quarter net sales were down less than 1%, better than the trend we saw during the first quarter, largely as a result of adjustments we made in response to the continued lower consumer demand driven by inflation and uncertainty related to ongoing global political, economic and public health...

Second quarter 2022 revenue of $14.1 million, bringing year to date revenue to $37.1 million. Reducing 2022 revenue guidance to $80-90 million to account for ongoing variability in core service business, macroeconomic and commercial factors. Maintaining substantial cash, cash equivalents, and current investments of $619.1 million at quarter end; Reducing operating expenses by $75 million through 2023-end to navigate market. Ongoing strategic plans including announced acquisition of Palamedrix for next-generation SomaScan reader; Illumina protein sequencer on track for 2024 launch; accelerating broad-based initiatives to grow scale and commercial team.BOULDER, Colo., Aug. 15, 2022 (GLOBE NEWSWIRE) —  SomaLogic, Inc., a leader in AI-data driven proteomics technology, today reported financial results for the quarter ended June 30,...

Quarterly revenue of $76.4 million, representing 27% growth year-over-year. Second quarter gross margin of 68.9% and gross profit growth of 19% year-over-year. Record gross margins in our US business of 74.2%. Active Buyers of 1.7 million and Orders of 1.7 million in Q2 2022, representing growth of 29% and 40% year-over-year, respectively. Published the 10th Annual Resale Report in May, revealing that the U.S. secondhand market is projected to more than double by 2026, reaching $82 billion.OAKLAND, Calif., Aug. 15, 2022 (GLOBE NEWSWIRE) — ThredUp Inc. (Nasdaq: TDUP), one of the largest online resale platforms for women’s and kids’ apparel, shoes, and accessories, announced today its financial results for the second quarter ended June 30, 2022. “Demonstrating the flexibility of our model to navigate a highly dynamic environment,...

Interim data from Part A of the RINGSIDE study demonstrated substantial initial anti-tumor activity for AL102 as a single agent and supports continued development More advanced and comprehensive data set from RINGSIDE to be presented at ESMO REHOVOT, Israel and WILMINGTON, Del., Aug. 15, 2022 (GLOBE NEWSWIRE) — Ayala Pharmaceuticals, Inc. (Nasdaq: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations, today announced second-quarter 2022 financial results and provided a corporate update. “We continue to make considerable progress across our pipeline, and we were particularly excited to announce interim results from the ongoing Phase 2/3 RINGSIDE trial evaluating AL102...